Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Pediatric Ulcerative Colitis
Interventions
DRUG

TA-650

TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.

Trial Locations (7)

Unknown

Investigational site, Chūbu

Investigational site, Hokkaido

Investigational site, Hokuriku

Investigational site, Kanto

Investigational site, Kinki

Investigational site, Kyusyu

Investigational site, Tōhoku

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY